Drug intelligence / Profile preview

HY-088

Development stage
Preclinical
Lead developer
Hyloris Pharmaceuticals
Modality
Nanoparticles → Drug Delivery Systems
Administration
Intravenous
01

Overview

HY-088 is an ultrasmall superparamagnetic iron oxide nanoparticle (USPIO) injection being developed as a contrast agent for magnetic resonance imaging (MRI). The drug consists of iron oxide crystals coated with polyacrylic acid (PAA) on the surface, which serves to stabilize the nanoparticles and enhance their biocompatibility. Developed by Sichuan Huiyu Seacross Pharmaceutical (a subsidiary of Huiyu Pharmaceutical) in collaboration with InnoStar Bio-tech, HY-088 functions by shortening the T2 and T2* relaxation times of water protons in the surrounding tissue, thereby improving image contrast. Preclinical studies in rat models have characterized its pharmacokinetic profile and tissue distribution, supporting its potential use in diagnostic imaging applications.

Other names
HY088HY-088HY 088

Beyond the preview

Go deeper on HY-088.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on HY-088.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call